Pfizer Falls on RFK’s Progress Towards Confirmation Despite Good Earnings. Its CEO is Unbothered.
CEO Albert Bourla says Pfizer has met the strategic goals it had set for itself in 2024, and that it was ‘executing ...
The faulty forecasts of pharma firm investors: Misguided cynics miss the promising prognosis for drugmakers Pfizer and Merck
Pfizer and Merck, ostensibly beleaguered drugmakers, have seen their shares battered despite reporting strong earnings.
MRNA, PFE, BNTX: Pharma Stocks Fall as RFK Jr. Set to Become U.S. Health Secretary
Shares of vaccine companies such as Moderna (MRNA), Pfizer (PFE) and BioNTech (BNTX), among others, are falling after a ...
Pfizer outlines 2025 R&D milestones and oncology growth opportunities
Bourla outlined 2025 priorities, which include improving R&D productivity, achieving margin expansion, and maintaining commercial excellence. He highlighted expectations for nine Phase 3 readouts, 13 ...
Pfizer shows profit growth from cost cuts and steadier COVID sales
Drugmaker Pfizer posted a better-than-expected fourth-quarter profit on Thursday, helped by cost cuts it began last year as ...
Pfizer CEO: Our stock is very cheap with lots of upside potential
In an interview on CNBC’s Mad Money, Dr. Albert Bourla said Pfizer (PFE) is focusing on business development to create shareholder value. “We ...
Pfizer Q4 Earnings: Solid Results, But Guidance And Patent Concerns Drive The Stock Down
Pfizer's Q4 2024 earnings beat expectations, but concerns over 2025 guidance and patent expirations led to stock decline. See ...
MediaPost2d
Pfizer CEO 'Cautiously Optimistic' As RFK Jr. Advances In Senate
CEO Bourla sees "a lot of opportunities that probably outweigh the risks" with the Trump administration, like working together on cancer treatments ...
FiercePharma11d
Pfizer avoids board nominations from Starboard as proxy fight rolls on: Bloomberg
Pfizer's CEO, Albert Bourla, Ph.D., has attempted to downplay the investor threat. At the J.P. Morgan Healthcare Conference ...
BioSpace3d
Pfizer Eyes Deals up to $15B, With ‘Fruitful’ China Discussions Ongoing
With just one asset in weight loss moving through the clinic, Pfizer targets the space for potential dealmaking, as well as bringing assets over from China.
Yahoo Finance14d
Pfizer’s Albert Bourla on Trump 2.0: ‘The status quo will collapse’
Few CEOs know the double-edged nature of dealing with US President Donald Trump as viscerally as Pfizer’s Albert Bourla. In his first term, Trump championed the $18 billion Operation Warp Speed ...